O-glycan profiling of serum glycan for potential renal cancer biomarkers

Science China Life Sciences

Volumn 56, Issue 8, 2013, Pages 739-744

  Gao, Yi ^a   Ma, Fei ^b,c   Zhang, Wei ^d   Zhong, Fan ^e   Tang, HaiLin ^d   Xu, DanFeng ^a   Zhao, Liang ^b  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d NATIONAL UNIVERSITY OF DEFENSE TECHNOLOGY   (China)

^e FUDAN UNIVERSITY   (China)

Author keywords

biomarkers; glycan; mass spectrometry; renal cell carcinoma

Indexed keywords

EID: 84881253716     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-013-4498-9     Document Type: Article

References (21)

1. Gutwein P, Schramme A, Sinke N, et al. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. Eur J Cancer, 2009, 45: 478-489.
2. Baldewijns M M, van Vlodrop I J, Schouten L J, et al. Genetics and epigenetics of renal cell cancer. Biochim et Biophys Acta, 2008, 1785: 133-155.
3. Zheng L G. Clinical value of IVU, CT and MRI in renal carcinoma. Chin Med Equip J, 2010, 8: 83-90.
4. Pantuck A J, Zisman A, Belldegrun A S. The changing natural history of renal cell carcinoma. J Urol, 2001, 166: 1611-1623.
5. Drucker B J. Renal cell carcinoma: current status and future prospects, Cancer Treat Rev, 2005, 31: 536-545.
6. Taniguchi N. Toward cancer biomarker discovery using the glycomics approach, Proteomics, 2008, 16: 3205-3208.
7. Ohtsubo K, Marth J D. Glycosylation in cellular mechanisms of health and disease. Cell, 2006, 126: 855-867.
8. Alper J. Glycobiology. Turning sweet on cancer. Science, 2003, 301: 159-160.
9. Villanueva J. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Proteome Res, 2005, 4: 1060-1072.
10. Reis C A, Osorio H, Silva L, et al. Alterations in glycosylation as biomarkers for cancer detection. J Clin Pathol, 2010, 63: 322-329.
11. Ishizuka A, Hashimto Y, Naka R, et al. Accumulation of free complex-type N-glycans in MKN7 and MKN45 stomach. Biochem J, 2008, 413: 227-237.
12. Kirmiz C, Li B, An H J, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics, 2007, 6: 43-55.
13. Kyselova Z, Mechref Y, Al Bataineh M M, et al. Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res, 2007, 6: 1822-1832.
14. Perret A G, Clemencon A, Li G, et al. Differential expression of prognostic markers in histological subtypes of papillary renal cell carcinoma. BJU Int, 2008, 102: 183-187.
15. Aubert S, Fauquette V, Hémon B, et al. MUC1, a new hypoxia inducible factor target gene, is an actor in clear renal cell carcinoma tumor progression. Cancer Res, 2009, 69: 5707-5715.
16. Morelle W, Michalski J C. Analysis of protein glycosylation by mass spectrometry. Nat Protoc, 2007, 2: 1585-1602.
17. Diamandis E P. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool. Mol Cell Proteomics, 2004, 3: 367-378.
18. Morelle W, Canis K, Chirat F, et al. The use of mass spectrometry for the proteomic analysis of glycosylation. Proteomics, 2006, 6: 3993-4015.
19. McLerran D F, Feng Z, Semmes O J, et al. Signal detection in high-resolution mass spectrometry data. J Proteome Res, 2008, 7: 276-285.
20. Zhang S, DeGraba T J, Wang H, et al. A novel peak detection approach with chemical noise removal using short-time FFT for prOTOF MS data. Proteomics, 2009, 9: 3833-3842.
21. Yang C, He Z, Yu W. Comparison of public peak detection algorithms for MALDI mass spectrometry data analysis. BMC Bioinformatics, 2009, 10: 4-17.